<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97356">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765257</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0138</org_study_id>
    <secondary_id>2007-002800-16</secondary_id>
    <nct_id>NCT01765257</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study</brief_title>
  <official_title>Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S, TEVA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Purpan (Toulouse)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Haut-Levêque (Pessac)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de la Côte Basque</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Poitiers (Poitiers)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Rennes (Rennes)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital R Salendro (Lille)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Dupuytren (Limoges)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Caremeau (NIMES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Pays D'Aix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone (MARSEILLE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Rothschild Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among the psychiatric symptoms observed in the premotor phase of Parkinson's disease (PD)
      and/or in &quot;de novo&quot; patients, apathy is relatively frequent (estimated to 23%). However, the
      neuropathological bases of apathy are still unknown. However, recent data suggests that
      apathy could be linked to a more specific dopaminergic denervation in the ventral striatum.

      Rasagiline increases the bioavailability of striatal endogenous dopamine by blocking the
      MAO-B. Some recent data suggest rasagiline could be effective to improve apathy in
      Parkinson's disease.

      The primary outcome is to demonstrate a significant reduction of apathy using the Lille
      apathy rating scale (LARS) in drug naive patients with early diagnosed Parkinson's disease,
      using a treatment by rasagiline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design :

      Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization
      1/1). Duration 3 months 16 recruiting centers in France

      Population :

      50 drug-naïve patients with Parkinson's disease, with apathy. 2 groups : 25 patients with
      placebo and 25 patients with rasagiline.

      3 visits

        -  Visit 1 : inclusion / randomisation/ first study medication dispensation

        -  Visit 2 (1.5 month after V1) : first evaluation and second study medication
           dispensation.

        -  Visit 3 (3 months after V1, final visit) : second evaluation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lille Apathy Rating Scale (LARS) score</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor assessment : Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive and anxiety symptoms : MADRS +  Hamilton anxiety scale</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self assessment of apathy :  Starkstein</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life :  PDQ 39</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive assessment: MATTIS dementia rating scale, MMSE, executive functions battery</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperdopaminergic symptoms : Parkinson's disease behavioral scale</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue assessment : Parkinson Fatigue Scale</measure>
    <time_frame>at the visit 3 (after 3 months of treatment)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Drug-naïve Patients With Parkinson's Disease</condition>
  <condition>Apathy</condition>
  <arm_group>
    <arm_group_label>rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZILECT®</intervention_name>
    <arm_group_label>rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Drug-naïve patients with Parkinson's disease  (UKPDBB criteria)

          -  No dementia (Mattis dementia rating scale &gt; 130; Mini Mental Sate Examination ≥26)

          -  No depression (MADRS &lt; 15)

          -  Criteria of apathy from Robert et al (2009)

          -  At least mild apathy (≥-21 to Lille Apathy Rating Scale)

          -  Age : 35-70 y

          -  Affiliation to social security

          -  Agreement of patients

        Exclusion Criteria:

          -  - Any antiparkinsonian treatment (L.dopa, dopamine agonists, MAO-B-I, amantadine,
             anticholinergics). Patients treated by dopamine agonists but who have stopped it more
             than 3 months before their inclusion can be included.

          -  Ongoing severe psychiatric or somatic diseases

          -  Others treatments :

          -  antipsychotics

          -  antidepressants and  anxiolytics (exclusion if the treatment is not stable the month
             before inclusion)

          -  psychostimulants (methylphenidate, adrafinil, modafinil, deanol, vitamin C,
             sulbutiamine, glutamic acid, aspartic acid)

          -  any contra-indication according to SmPC

          -  patients under guardianship

          -  Women without efficient contraception

          -  Person who participate to an other study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis PEZET</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-naïve patients with Parkinson's disease</keyword>
  <keyword>Apathy</keyword>
  <keyword>Rasagiline</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
